gms | German Medical Science

22. Jahrestagung der Gesellschaft für Arzneimittelanwendungsforschung und Arzneimittelepidemiologie (GAA)

Gesellschaft für Arzneimittelanwendungsforschung und Arzneimittelepidemiologie

03.12. - 04.12.2015, Dresden


Meeting Abstract (15gaa01)

Acceptability and feasibility of the medication plan vs. 2.0 in the model region of Erfurt: a prospective cohort study

Brell D, Fenske D, Thuermann P
Meeting Abstract (15gaa02)

Adherence to Disease Modifying Drugs among Patients with Multiple Sclerosis in Germany: A Retrospective Cohort Study

Hansen K, Schuessel K, Kieble M, Werning J, Schulz M, Friis R, Poehlau D, Schmitz N, Kugler J
Meeting Abstract (15gaa03)

Can claims data help validating drug risk signals? A case report

Krieg EM, Ganso M, Gradl G, Goebel R, Schulz M
Meeting Abstract (15gaa04)

Comparative evaluation of methods approximating drug prescription durations in claims data: Modeling, simulation, and application to real data

Meid A, Quinzler R, Adler JB, Heider D, König HH, Haefeli WE
Meeting Abstract (15gaa05)

DOACs – whom for? Secondary data analysis of current prescription trends

Eichler U, Selke GW, Langner I
Meeting Abstract (15gaa06)

Graph theoretic analysis of neighbourhood relations with respect to simultaneously applied drugs

Schuster R
Meeting Abstract (15gaa07)

Individualized versus standardized risk assessment in patients at high risk for adverse drug reactions (IDrug) – a pragmatic trial in individualized medicine

Kaumanns K, Kastenmüller K, Coch C, von Mallek D, Leuchs AK, Benda N, Meier F, Schöffski O, Holdenrieder S, Hartmann G, Weckbecker K, Stingl J
Meeting Abstract (15gaa08)

KAMPI – Project to promote evidence-based drug information in German hospital pharmacies

Gruber AC, Amann S, Mildner C, Querbach C, Schuhmacher C, Strobach D, Vetter-Kerkhoff C
Meeting Abstract (15gaa09)

Medication safety – Risk of statin-induced myopathie

Farker K, Leichenberg K, Hartmann M
Meeting Abstract (15gaa10)

Morbidity Related Groups (MRG) and drug economic efficiency index – a new concept after the age of "Richtgrößen" benchmarks in Germany.

Schuster R
Meeting Abstract (15gaa11)

Neuro-Bio-Behavioral Mechanisms of Placebo and Nocebo Responses: Implications for Clinical Trials and Clinical Practice

Schedlowski M
Meeting Abstract (15gaa12)

Physicians ask Pharmacists – Analysis of enquiries answered by the drug information service of the pharmacy in a university hospital 2005–2014

Vetter-Kerkhoff C, Lachenmayr S, Kufeldt J, Andraschko M, Strobach D
Meeting Abstract (15gaa13)

Polypharmacy in Germany: Results of the German National Health Interview and Examination Survey 1998 (GNHIES 1998) and the German Health Interview and Examination Survey for Adults Wave 1 (DEGS1, 2008–2011)

Knopf H
Meeting Abstract (15gaa14)

Potentially Inappropriate Medications (PIM) in the acute inpatient geriatric institution of the university hospital in Jena/Thuringia

Al-Otti S, Kwetkat A, Hippius M
Meeting Abstract (15gaa15)

Private prescriptions of benzodiazepines and Z-drugs for statutory health insurance patients

Puteanus U, Beigi A, Rueter T, Hempel G
Meeting Abstract (15gaa16)

Rationale Pharmakotherapie bei Patienten mit Diabetes mellitus Typ 2

Luebeck R, Karimova K, Hammer M, Guenthlin C, Beyer M
Meeting Abstract (15gaa17)

The Early Benefit Assessment and the Single Technology Appraisal from NICE – comparison of the HTA methods and their influence on prescribing practice

Lämmel J, Maywald U, Knoth H, Schmitt J, Nagels K
Meeting Abstract (15gaa18)

Therapy of Hepatitis C: embracing change

Langner I, Selke GW, Eichler U
Meeting Abstract (15gaa19)

VKA vs. NOAC advantages in application-related patient safety

Krek C, Grave B, Heeke A
Meeting Abstract (15gaa20)

Why do family doctors prescribe potentially inappropriate medication to elderly patients?

Voigt K, Gottschall M, Köberlein-Neu J, Bergmann A